Research & Education

Taking Bites of the KRAS Pie: Co-occurring mutations define KRAS subsets with distinct biology, immune profiles, and drug vulnerabilities

Wednesday, January 27, 2016 at 9 p.m. EST - Recording Available
 John Heymach  

John Heymach, MD
Professor and Chair
Thoracic/Head and Neck Medical Oncology,
The University of Texas
MD Anderson Cancer Center

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Division of Oncology
Washington University School of Medicine

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

      Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Taking Bites of the KRAS Pie: Co-occurring mutations define KRAS subsets with distinct biology, immune profiles, and drug vulnerabilities

Date of Activity:

 

Jan 27, 2016

Faculty/Speaker(s):

Financial DISCLOSURES

 

John Heymach, MD-Speaker-Research Funding from: Astra Zeneca, GlaxoSmithKline, Bayer.

Advisory Board for: Genentech, Astra Zeneca, GlaxoSmithKline, Eli Lilly, Boehringer-Ingelheim, Synta and Exelixis

Moderator: Ramaswamy Govindan, MD – Speakers or Advisory Board , Honoraria and consulting with the following: BI, GSK, Celgene, Roche, Bayer, Genentech, Clovis, Helsinn Healthcare, ARAID Pharmaceuticals, Astellas; Honoraruim with the following: Baxalta, Roche

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

         No

If yes, please list:

 

IASLC continues the Lung Cancer this LIVE WEBINAR featuring Dr. John Heymach.

KRAS is the most common oncogenic driver in non-small cell lung cancer and other solid tumors. Despite great rapid recent progress in the treatment other oncogene-driven malignancies, to date there are still no targeted therapies for KRAS mutant lung cancers. A major obstacle to progress in this area is the heterogeneity among different KRAS tumors. Here, we discuss how co-occurring genomic alterations impact KRAS signaling and define distinct KRAS subgroups with different drug response patterns and immune profiles, and how such an understanding of Kras subsets can lead to development of more refined therapeutic approaches.

After attending this session, participants will:

  1. Compare the prevalence of KRAS mutations in NSCLC and other solid tumors and the impact of KRAS on prognosis and response to available targeted drugs.
  2. Recognize the potential impact of different KRAS alleles (e.g. G12C, G12D) on KRas signaling and outcome.
  3. Recognize that co-occurring mutations in tumor suppressors (e.g. P53, LKB1, CDKN2A) can impact the biology and immune profile of KRAS mutant lung cancer and its likelihood of response to different types of therapy.

Following the presentation, there was ample time for discussion and a question/answer session. Attendees can submit questions and comments to Dr. Heymach via Internet chat.

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

 

CME INFORMATION:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

KRAS is the most common oncogenic driver in non-small cell lung cancer and other solid tumors. Despite great rapid recent progress in the treatment other oncogene-driven malignancies, to date there are still no targeted therapies for KRAS mutant lung cancers. A major obstacle to progress in this area is the heterogeneity among different KRAS tumors. Here, we discuss how co-occurring genomic alterations impact KRAS signaling and define distinct KRAS subgroups with different drug response patterns and immune profiles, and how such an understanding of Kras subsets can lead to development of more refined therapeutic approaches.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

DOWNLOAD RECORDING

 

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

IASLC Lung Cancer Grand Rounds webinars will continue throughout 2016. The goal is to hold one program monthly. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar. 

Use the Time Zone Converter